MRNA is in a strong uptrend
+83
BearishSidewaysBullish
Why this reading
- Price is above its 200-day average ($85.65).
- The 50-day average is rising (+2.06%/day).
- Price is above its 50-day average ($180.62).
- 50-day average is above the 200-day (long-term structure is up).
- Recent swings show higher highs and higher lows.
- MACD momentum is weakening and the MACD line is above zero.
Price chart
Lower pane: RSI (14) with 70 and 30 marked. Arrows mark candlestick patterns.
Indicators
| Indicator | Value | Reading | What it means |
|---|---|---|---|
| Moving averages | Bullish stack | Bullish | 20-day $213.38, 50-day $180.62, 200-day $85.65 |
| RSI (14) | 57.1 | Bullish | Buyers have the upper hand. |
| MACD (12,26,9) | -3.78 | Bearish | MACD is below its signal line. |
| Bollinger %B | 0.61 | Neutral | Bands are 29.7% wide. |
| Volatility (ATR 14) | $20.28 (9.2%) | Neutral | High daily volatility — expect large swings. |
| Volume vs 20d avg | 0.31× | Neutral | Light volume — the latest move has little participation. |
| 52-week range | 85% | Bullish | Low $22.28, high $254.43 |
Key levels
- $254.43Resistance, 1 touch+15.3%
- $220.68Last close
- $55.32Support, 5 touches-74.9%
- $47.84Support, 5 touches-78.3%
- $45.67Support, 4 touches-79.3%
Recent candlestick patterns
- Evening StarBearish
Up candle, small pause candle, then a strong down candle — a three-bar reversal pattern.
- Shooting StarBearish
Long upper wick after an advance — buyers were rejected at higher prices.
- DojiNeutral
Open and close nearly equal — indecision between buyers and sellers.
- DojiNeutral
Open and close nearly equal — indecision between buyers and sellers.
Latest news
- Moderna CEO Discusses Potential 2028 Launch for Skin Cancer Vaccine in Europefiscal.ai
- Law Firm Announces Investigation into Moderna, Inc. Following Clinical Trial Data Leakfiscal.ai
- William Blair Initiates and Downgrades Moderna to Market Performfiscal.ai
- This M&T Bank Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesdaybenzinga
- William Blair Takes a Shot at Moderna Stock: Downgrade to Market Perform After a 545% Runbenzinga